Lionco Pharmaceutical Group Co., Ltd.

Lionco Pharmaceutical Group Co., Ltd. faced notable volatility, with its stock declining significantly today, contrasting with the modest gain of the China Shanghai Composite. The company has experienced a substantial drop over the past five years and reported concerning financial metrics, including a low Return on Capital Employed and negative operating cash flow.

Lionco Pharmaceutical Group Co., Ltd. faced notable stock volatility, hitting an intraday low amid broader market declines. Despite a recent monthly rise, the company has struggled with long-term financial challenges, including decreasing net sales and operating profit, alongside low profitability metrics and negative returns on equity.

Lionco Pharmaceutical Group Co., Ltd. saw a notable stock price increase on July 13, 2026, amid a broader market decline. The company has experienced significant short-term gains, but faces long-term challenges, including declining net sales and a high debt-equity ratio, indicating potential financial instability.

Lionco Pharmaceutical Group Co., Ltd. saw a notable increase in its stock performance on June 23, 2026, achieving an intraday high amid a declining broader market. Despite recent gains and significant short-term growth, the company faces long-term challenges, including declining net sales and negative operating cash flow.

Lionco Pharmaceutical Group Co., Ltd. saw a notable increase in its stock today, contrasting with a decline in the broader market. However, long-term performance reveals challenges, including a significant drop in stock value over the past year and five years, alongside low financial indicators and declining sales.